CINV Guideline — Part 3: Recommended Antiemetic Regimens and Special Populations

Guideline-recommended antiemetic regimens by emetogenic risk level, multi-day chemotherapy protocols, oral chemotherapy CINV, radiation-induced nausea and vomiting, breakthrough and refractory CINV management, and considerations for pediatric, geriatric, and organ-impaired populations.

guidelines•Mar 2026•guidelines

Antiemetic regimen selection must be guided by the emetogenic risk classification of the chemotherapy regimen. The following recommendations represent the current evidence-based consensus from major international guideline bodies.123

High Emetogenic Chemotherapy (HEC) — Recommended Regimens

The standard of care for HEC prophylaxis is a four-drug combination regimen. All four agents should be initiated before chemotherapy on Day 1.

Preferred Four-Drug Regimen (HEC)

DayNK1 RA5-HT3 RADexamethasoneOlanzapine
Day 1 (pre-chemo)Aprepitant 125 mg PO OR Fosaprepitant 150 mg IV OR Netupitant 300 mg/palonosetron 0.5 mg PO (AKYNZEO) OR Fosnetupitant 235 mg/palonosetron 0.25 mg IV (AKYNZEO IV) OR Rolapitant 180 mg POPalonosetron 0.25 mg IV OR Ondansetron 8–16 mg IV OR Granisetron 1 mg IV or 2 mg PO12 mg IV or PO (with aprepitant or netupitant) OR 20 mg IV or PO (with rolapitant or without NK1 RA)5–10 mg PO at bedtime
Day 2Aprepitant 80 mg PO (if using 3-day oral aprepitant; not needed with fosaprepitant, netupitant, or rolapitant)—8 mg PO once daily5–10 mg PO at bedtime
Day 3Aprepitant 80 mg PO (if using 3-day oral aprepitant)—8 mg PO once daily5–10 mg PO at bedtime
Day 4——8 mg PO once daily5–10 mg PO at bedtime

Key notes on HEC regimens:

  • Olanzapine 5 mg is increasingly preferred over 10 mg based on randomized non-inferiority data demonstrating comparable nausea and vomiting control with significantly less sedation.4
  • When using fosaprepitant (single IV dose) or netupitant/fosnetupitant (single dose), Days 2–3 oral aprepitant is not needed.
  • When using rolapitant, dexamethasone does not require dose reduction (rolapitant does not inhibit CYP3A4).
  • Palonosetron is the preferred 5-HT3 RA for single-day dosing (long half-life); however, ondansetron and granisetron remain acceptable alternatives.
  • Dexamethasone on Days 2–4 may be omitted if olanzapine is included and the patient does not tolerate corticosteroids, though this approach is not yet fully validated.

Cisplatin-Based HEC: Additional Considerations

Cisplatin is the most emetogenic single agent. All cisplatin-containing regimens at any dose should receive four-drug HEC prophylaxis. Delayed CINV is especially prominent with cisplatin, typically peaking at 48–72 hours and persisting for up to 5 days. Extended dexamethasone (through Day 4) is particularly important for cisplatin-based regimens.

AC/EC-Based HEC (Anthracycline + Cyclophosphamide)

AC and EC combinations are classified as HEC. The four-drug regimen above is recommended. Some guidelines suggest that dexamethasone can be limited to Day 1 only in AC/EC regimens when olanzapine is included, given data suggesting olanzapine provides adequate delayed-phase protection.5 This dexamethasone-sparing approach may be appropriate for select patients but remains a topic of ongoing investigation.

Carboplatin AUC ≥4

Carboplatin at AUC ≥4 has been reclassified as HEC based on evidence of high rates of delayed emesis. The four-drug HEC regimen is recommended. Carboplatin at AUC <4 remains classified as MEC.

Moderately Emetogenic Chemotherapy (MEC) — Recommended Regimens

Standard Two-Drug Regimen (MEC)

Day5-HT3 RADexamethasone
Day 1 (pre-chemo)Palonosetron 0.25 mg IV (preferred) OR Ondansetron 8 mg IV or 8 mg PO OR Granisetron 1 mg IV or 2 mg PO8 mg IV or PO
Days 2–3— (if palonosetron used on Day 1) OR Ondansetron 8 mg PO q12h or Granisetron 1 mg PO q12h (if shorter-acting 5-HT3 RA used)8 mg PO once daily (optional; consider for agents with significant delayed CINV risk, such as oxaliplatin, irinotecan, or cyclophosphamide)

Palonosetron is the preferred 5-HT3 RA for MEC based on randomized trial data demonstrating superior delayed-phase control compared with first-generation 5-HT3 RAs.6

Three-Drug Regimen (MEC — For Higher-Risk MEC or Select Patients)

An NK1 RA may be added to the two-drug MEC regimen for:

  • Patients with additional risk factors (young age, female sex, prior CINV)
  • MEC agents with significant delayed CINV potential (oxaliplatin, irinotecan, cyclophosphamide <1500 mg/m²)
  • Patients who have experienced breakthrough CINV with two-drug MEC prophylaxis
DayNK1 RA5-HT3 RADexamethasone
Day 1Aprepitant 125 mg PO or Fosaprepitant 150 mg IV or Netupitant/palonosetronPalonosetron 0.25 mg IV or Ondansetron 8 mg IV8 mg IV or PO (dose-adjust with aprepitant/netupitant)
Days 2–3Aprepitant 80 mg PO (if 3-day oral)—8 mg PO daily (optional)

Olanzapine in MEC

Olanzapine may be considered as part of the MEC regimen for patients at high risk based on patient-specific factors, though it is not universally recommended as standard prophylaxis for MEC. When used, dosing is 5 mg PO daily on Days 1–3.

Low Emetogenic Chemotherapy (LEC) — Recommended Regimens

RegimenDosing
Preferred: Dexamethasone alone8 mg IV or PO on Day 1 before chemotherapy (some guidelines suggest 4–8 mg)
Alternative: 5-HT3 RA aloneOndansetron 8 mg PO or IV OR Granisetron 1 mg PO or IV on Day 1
Alternative: Dopamine antagonistProchlorperazine 10 mg PO or IV on Day 1 (less commonly used)
  • No routine prophylaxis for the delayed phase is recommended for LEC
  • If a patient experiences breakthrough CINV with LEC, escalate to the MEC prophylactic regimen for subsequent cycles

Minimal Emetogenic Chemotherapy — Recommended Regimens

  • No routine antiemetic prophylaxis is recommended before chemotherapy
  • Rescue antiemetics should be available if nausea or vomiting develops
  • If symptoms occur, use any single agent (ondansetron 8 mg PO, prochlorperazine 10 mg PO, or metoclopramide 10–20 mg PO)

Summary Table — Recommended Prophylactic Regimens

Emetogenic RiskDay 1 RegimenDays 2–4
HECNK1 RA + 5-HT3 RA + Dexamethasone 12 mg + Olanzapine 5–10 mgDexamethasone 8 mg daily (Days 2–4) + Olanzapine 5–10 mg daily (Days 2–4) ± Aprepitant 80 mg (Days 2–3 if oral regimen)
MEC5-HT3 RA (palonosetron preferred) + Dexamethasone 8 mg ± NK1 RA± Dexamethasone 8 mg daily (Days 2–3)
LECDexamethasone 8 mg OR 5-HT3 RANone
MinimalNone (rescue available)None

Multi-Day Chemotherapy Protocols

Multi-day chemotherapy regimens (e.g., BEP for germ cell tumors, hyper-CVAD for leukemia, cisplatin-based regimens given over 3–5 days) present unique antiemetic challenges because the cumulative emetogenic effect increases with each day of treatment.7

General Principles

  1. Administer a 5-HT3 RA and dexamethasone before each day of chemotherapy throughout the multi-day regimen
  2. Use an NK1 RA on Day 1 of the multi-day regimen if any single day’s chemotherapy qualifies as HEC or MEC. For agents with long half-lives (fosaprepitant, netupitant, rolapitant), a single dose on Day 1 may suffice for the entire multi-day block.
  3. Continue dexamethasone for 2–3 days beyond the last day of chemotherapy to cover the delayed phase
  4. Olanzapine may be added to the regimen (5 mg PO at bedtime daily) throughout the multi-day block and for 2–3 days following the last chemotherapy dose
  5. Palonosetron may need to be re-dosed if the multi-day regimen exceeds 3 days (given its ~40-hour half-life, dosing every 2–3 days is reasonable)

Example: 5-Day Cisplatin Protocol

Day5-HT3 RANK1 RADexamethasoneOlanzapine
Day 1Palonosetron 0.25 mg IV or Ondansetron 8 mg IVAprepitant 125 mg PO or Fosaprepitant 150 mg IV12 mg IV5 mg PO HS
Day 2Ondansetron 8 mg IV (if not using palonosetron) or none (if palonosetron Day 1)Aprepitant 80 mg PO (if using 3-day oral)8 mg IV or PO5 mg PO HS
Day 3Palonosetron 0.25 mg IV (re-dose) or Ondansetron 8 mg IVAprepitant 80 mg PO (last dose)8 mg IV or PO5 mg PO HS
Day 4Ondansetron 8 mg IV—8 mg IV or PO5 mg PO HS
Day 5Palonosetron 0.25 mg IV or Ondansetron 8 mg IV—8 mg IV or PO5 mg PO HS
Days 6–8——8 mg PO daily5 mg PO HS (optional)

Oral Chemotherapy-Induced CINV

Many oral antineoplastic agents carry moderate emetogenic potential and are taken daily over extended periods, creating a chronic CINV scenario that differs from the episodic pattern of IV chemotherapy.8

General Principles for Oral Agents

  1. Assess the emetogenic risk of the oral agent using the oral classification tables (see Part 1)
  2. For moderate-risk oral agents (e.g., temozolomide, cyclophosphamide PO, crizotinib): prescribe a 5-HT3 RA (ondansetron 8 mg PO) before each dose or daily, with or without dexamethasone on Day 1 of each cycle
  3. For low-risk oral agents (e.g., capecitabine, olaparib, lenalidomide): prescribe as-needed antiemetics (ondansetron 8 mg PO PRN or prochlorperazine 10 mg PO PRN); routine prophylaxis may not be necessary
  4. For minimal-risk oral agents: no routine prophylaxis; rescue antiemetics available PRN
  5. NK1 RAs are generally not indicated for oral chemotherapy-induced CINV prophylaxis unless the agent is classified as high emetogenic risk
  6. Long-term antiemetic use requires monitoring for chronic side effects (e.g., constipation with 5-HT3 RAs, QTc prolongation)

Temozolomide-Specific Recommendations

Temozolomide, commonly used for glioblastoma (often with concurrent cranial radiation), requires special attention:

  • Standard dosing (75 mg/m² daily during radiation): Ondansetron 8 mg PO 30 minutes before each temozolomide dose
  • Adjuvant dosing (150–200 mg/m² Days 1–5 of 28-day cycle): 5-HT3 RA before each dose; consider adding dexamethasone on Day 1 of each cycle (note that many of these patients are already on dexamethasone for cerebral edema)

Radiation-Induced Nausea and Vomiting (RINV)

Radiation therapy can independently cause nausea and vomiting. The risk depends primarily on the radiation field, dose per fraction, total dose, and irradiated volume. Combined chemoradiation carries higher emetogenic risk than either modality alone.9

Emetogenic Risk Classification of Radiation Therapy

Emetogenic RiskRadiation Field/Site
High (>90%)Total body irradiation (TBI); total nodal irradiation
Moderate (60–90%)Upper abdomen; craniospinal; half body irradiation
Low (30–60%)Lower thorax; pelvis; cranium (whole brain, stereotactic radiosurgery); head and neck
Minimal (<30%)Extremities; breast; head and neck (limited field)

RINV Prophylaxis Recommendations

Radiation Emetogenic RiskRecommended Prophylaxis
High5-HT3 RA (ondansetron 8 mg PO/IV or granisetron 2 mg PO) before each fraction + Dexamethasone 4 mg daily during radiation
Moderate5-HT3 RA before each fraction ± Dexamethasone (for the first 5 fractions, then as needed)
Low5-HT3 RA before each fraction PRN (i.e., rescue use or prophylactic if symptoms develop)
MinimalRescue therapy only (ondansetron 8 mg PO PRN or prochlorperazine 10 mg PO PRN)

Combined Chemoradiation

When chemotherapy and radiation are given concurrently, antiemetic prophylaxis should be based on the higher emetogenic risk of the two modalities. In most cases, the chemotherapy component will drive the antiemetic regimen. The radiation field may add to the overall emetogenic burden and should be considered when selecting prophylaxis.

Breakthrough CINV Management

Breakthrough CINV is defined as nausea and/or vomiting occurring despite the administration of optimal prophylactic antiemetics according to guideline recommendations.10

Principles of Breakthrough CINV Management

  1. Verify guideline-concordant prophylaxis was administered before diagnosing true breakthrough CINV
  2. Add an agent from a different pharmacological class than those used for prophylaxis
  3. Reassess for other causes of nausea/vomiting: bowel obstruction, CNS metastases, electrolyte abnormalities (hypercalcemia, hyponatremia), medications (opioids, antibiotics), gastroparesis, constipation
  4. Administer rescue agents on a scheduled basis (around-the-clock dosing) rather than PRN for the first 48–72 hours
  5. Do not repeat agents that have already failed at the prescribed prophylactic dose
AgentDoseNotes
Olanzapine10 mg PO once daily for 3 daysRecommended as first-line breakthrough therapy by major guidelines; strong evidence from randomized trials
Prochlorperazine10 mg PO or IV q6h PRNWidely available; risk of EPS
Metoclopramide10–20 mg PO or IV q6h PRNProkinetic benefit; avoid if bowel obstruction suspected
Lorazepam0.5–2 mg PO/IV q6h PRNParticularly useful for anxiety-associated nausea and anticipatory CINV
Dexamethasone8–12 mg PO/IV once dailyIf not already included in the prophylactic regimen
Haloperidol0.5–2 mg PO/IV q4–6h PRNFor refractory cases
Dronabinol2.5–5 mg PO q4–6h PRNFor refractory CINV after failure of standard agents
Nabilone1–2 mg PO q12hFor refractory CINV after failure of standard agents
Scopolamine1.5 mg transdermal patch q72hAdjunctive; for vestibular/motion component
5-HT3 RA (different agent or route)Ondansetron 8 mg PO q8h, Granisetron transdermal patchIf not used for prophylaxis at maximum dose, or switch formulation

Refractory CINV Management

For patients with refractory CINV (persistent symptoms despite optimal prophylaxis and breakthrough management across multiple cycles):

  1. Reassess the antiemetic regimen — ensure four-drug HEC-level prophylaxis is being used
  2. Consider escalating to the next emetogenic risk tier for prophylaxis
  3. Add olanzapine if not already in the regimen
  4. Rotation of 5-HT3 RA — switch from ondansetron to palonosetron or vice versa
  5. Consider adding gabapentin 300 mg PO TID (limited evidence)
  6. Address anticipatory CINV with behavioral therapy and/or lorazepam
  7. Multidisciplinary palliative care consultation may be appropriate for refractory cases

Special Populations

Pediatric Patients

Antiemetic recommendations for pediatric patients are adapted from adult guidelines with age- and weight-appropriate dosing adjustments.11

AgentPediatric DosingNotes
Ondansetron0.15 mg/kg/dose IV (max 16 mg) or 0.15 mg/kg/dose PO (max 8 mg) before chemotherapy; may repeat q8hMost commonly used 5-HT3 RA in pediatrics
Granisetron10–40 mcg/kg/dose IV (max 1 mg) before chemotherapy
Dexamethasone3–6 mg/m²/dose IV or PO (max 20 mg) on Day 1; 1.5–3 mg/m²/dose (max 8 mg) on subsequent daysAvoid if dexamethasone is part of the chemotherapy regimen (e.g., ALL protocols)
AprepitantAge ≥12 years: adult dosing; Age 6 months to <12 years: Day 1: 3 mg/kg PO (max 125 mg), Days 2–3: 2 mg/kg PO (max 80 mg)FDA-approved for age ≥6 months
FosaprepitantAge ≥12 years: 150 mg IV; Age 6 months to <12 years: 4 mg/kg IV (max 150 mg) as single dose
OlanzapineLimited pediatric data. Some centers use 2.5–5 mg PO in adolescents. Not routinely recommended in young children due to metabolic and sedation concerns.
Lorazepam0.02–0.05 mg/kg/dose IV or PO (max 2 mg) q6h PRNFor anticipatory CINV and adjunctive use

Pediatric-specific considerations:

  • Children over age 5 are generally at higher risk for CINV than younger children
  • Anticipatory CINV is common in pediatric patients and develops more rapidly than in adults
  • Behavioral interventions (distraction, guided imagery, hypnosis) are particularly effective in children
  • EPS risk with dopamine antagonists (metoclopramide, prochlorperazine) is higher in children than adults — use with caution

Geriatric Patients

ConsiderationRecommendation
Olanzapine dosingStart with 5 mg (not 10 mg) due to increased sedation sensitivity and fall risk
BenzodiazepinesUse with caution; increased risk of sedation, confusion, delirium, and falls. Lorazepam 0.5 mg is a reasonable starting dose.
DexamethasoneIncreased risk of hyperglycemia, insomnia, and delirium in elderly patients; monitor closely. Consider lower doses (4–8 mg) when clinically acceptable.
Dopamine antagonistsIncreased EPS risk; metoclopramide and prochlorperazine should be used at lower doses and with monitoring
Anticholinergic agentsAvoid or minimize use of scopolamine and promethazine due to risk of confusion, urinary retention, and delirium
QTc prolongationHigher baseline risk; avoid ondansetron IV >16 mg; monitor ECG if using multiple QTc-prolonging medications
PolypharmacyReview all medications for emetogenic potential (opioids, antibiotics, iron supplements) and drug-drug interactions
Renal functionAdjust doses for agents with significant renal clearance; monitor electrolytes closely

Renal Impairment

AgentRenal Dosing Adjustment
OndansetronNo dose adjustment required
GranisetronNo dose adjustment required
PalonosetronNo dose adjustment required
AprepitantNo dose adjustment required
DexamethasoneNo dose adjustment required
OlanzapineNo specific renal adjustment; use clinical judgment
MetoclopramideReduce dose by 50% for CrCl <40 mL/min (risk of EPS and accumulation)
GabapentinDose adjustment required based on CrCl

Hepatic Impairment

AgentHepatic Dosing Adjustment
OndansetronMaximum 8 mg/day in severe hepatic impairment (Child-Pugh C)
GranisetronNo specific adjustment, but use with caution
PalonosetronNo dose adjustment required
AprepitantMild–moderate impairment (Child-Pugh A, B): no adjustment. Severe impairment (Child-Pugh C): insufficient data — use with caution.
DexamethasoneNo specific adjustment; metabolized hepatically — monitor for prolonged effects
OlanzapineConsider dose reduction in significant hepatic impairment; starting dose of 5 mg recommended
MetoclopramideReduce dose in moderate–severe hepatic impairment

Patients with Pre-existing Nausea or Chronic Nausea

Patients with ongoing nausea unrelated to chemotherapy (from disease burden, opioid use, gastroparesis, or other causes) require:

  1. Identification and treatment of the underlying cause
  2. Optimization of baseline antiemetic therapy before initiation of emetogenic chemotherapy
  3. Standard guideline-concordant CINV prophylaxis in addition to baseline antiemetic management
  4. Close monitoring and lower threshold for adding breakthrough agents

References

  1. Hesketh PJ, Kris MG, Basch E, et al. “Antiemetics: ASCO Guideline Update.” Journal of Clinical Oncology, 38(24): 2782–2797, 2020. American Society of Clinical Oncology (ASCO). DOI: 10.1200/JCO.20.01296 ↩︎

  2. Roila F, Molassiotis A, Herrstedt J, et al. “2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting.” Annals of Oncology, 27(suppl 5): v119–v133, 2016. Multinational Association of Supportive Care in Cancer (MASCC) and European Society for Medical Oncology (ESMO). Updated through 2023 consensus. ↩︎

  3. National Comprehensive Cancer Network (NCCN). “NCCN Clinical Practice Guidelines in Oncology: Antiemesis.” Version 1.2025. ↩︎

  4. Hashimoto H, Abe M, Tokuyama O, et al. “Olanzapine 5 mg with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.” Lancet Oncology, 21(2): 242–249, 2020. DOI: 10.1016/S1470-2045(19)30678-3 ↩︎

  5. Ithimakin S, Theeratrakul P, Laocharoenkiat A, et al. “Randomized, double-blind, placebo-controlled study of aprepitant plus ondansetron and dexamethasone versus ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin.” Supportive Care in Cancer, 25: 1025–1033, 2017. ↩︎

  6. Saito M, Aogi K, Sekine I, et al. “Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.” Lancet Oncology, 10(2): 115–124, 2009. DOI: 10.1016/S1470-2045(08)70313-9 ↩︎

  7. Albany C, Brames MJ, Fausel C, et al. “Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens.” Journal of Clinical Oncology, 30(32): 3998–4003, 2012. DOI: 10.1200/JCO.2011.39.8545 ↩︎

  8. Hesketh PJ, Kris MG, Basch E, et al. “Antiemetics: ASCO Guideline Update.” Journal of Clinical Oncology, 38(24): 2782–2797, 2020 (Section: Oral Chemotherapeutic Agents). American Society of Clinical Oncology (ASCO). ↩︎

  9. Dennis K, Maranzano E, De Angelis C, et al. “Radiotherapy-induced nausea and vomiting.” In: Navari RM (ed), Management of Chemotherapy-Induced Nausea and Vomiting: New Agents and New Uses of Current Agents. Springer, pp. 181–202, 2016. ↩︎

  10. Navari RM, Aapro M. “Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting.” New England Journal of Medicine, 374(14): 1356–1367, 2016. DOI: 10.1056/NEJMra1515442 ↩︎

  11. Dupuis LL, Sung L, Molassiotis A, et al. “2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children.” Supportive Care in Cancer, 25: 323–331, 2017. DOI: 10.1007/s00520-016-3384-y ↩︎